Inclusion Criteria:

          -  Patients must have a confirmed diagnosis of CD22-positive, Philadelphia chromosome
             (Ph)-positive or Ph-negative B-cell acute lymphoblastic leukemia or lymphoblastic
             lymphoma. CD22 expression will be determined by multiparameter flow cytometry (MFC) or
             immunohistochemistry.

          -  Relapsed or refractory disease, as defined by any of the following:

               -  Unable to achieve complete response (CR) despite >= 4 weeks of initial course of
                  systemic therapy.

               -  Recurrence of disease at any point after CR was achieved.

                    -  (Note: patients with Ph-positive disease must have received >= 1 second- or
                       third-generation ABL kinase inhibitor as part of their prior treatment to be
                       eligible.)

          -  Detectable disease, as defined by any of the following:

               -  Presence of >= 5% abnormal blasts in the bone marrow or peripheral blood by
                  morphology or MFC.

               -  Patients with isolated extramedullary disease will be permitted if there is >= 1
                  site of disease that measures >= 1.5 cm in longest diameter on cross-sectional
                  imaging.

          -  Absolute neutrophil count (ANC) >= 1,000/uL.

          -  Hemoglobin >= 8 g/dL.

          -  Platelets >= 50,000/uL.

          -  Note: Transfusions and growth factor support will be permitted within 3 days of
             initiation of study treatment to reach these thresholds. As patients with
             relapsed/refractory ALL frequently have cytopenias due to marrow infiltration by the
             disease, no hematologic parameters will be required for enrollment if cytopenias can
             be attributed to disease.

          -  Total serum bilirubin =< 1.5 x upper limit of normal (ULN); (unless due to Gilbert
             syndrome or hemolysis; =< 2 x ULN for hepatic abnormalities considered
             disease-related).

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN.

          -  Serum creatinine =< 1.5 x ULN or serum creatinine level associated with a measured or
             calculated creatinine clearance of >= 40 mL/min.

          -  Corrected QT (QTc) interval =< 500 msec; if assessed, left ventricular ejection
             fraction >= 40%.

          -  An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

          -  Must agree to the use of effective contraception while on study treatment, unless they
             are highly unlikely to conceive (defined as [1] surgically sterilized, or [2] women
             who are and men whose sexual partner[s] is/are postmenopausal [i.e., a woman who is >
             50 years old or who has not had menses for >= 1 year], or [3] not heterosexually
             active for the duration of the study).

        Exclusion Criteria:

          -  Patients with a circulating blast count of > 50,000/uL; systemic therapy with either
             hydroxyurea, vincristine, and/or corticosteroids will be permitted within 3 days of
             initiation of study treatment to reduce the blast count.

          -  Except for management of circulating blasts noted above, adequate duration from prior
             therapy must be achieved before initiation of study treatment, as defined below:

               -  No cytotoxic or targeted systemic therapy < 2 weeks or 5 half-lives (whichever is
                  shorter).

               -  No blinatumomab < 2 weeks.

               -  No radiation therapy < 4 weeks.

               -  No monoclonal antibody therapy < 6 weeks (except for prior InO, as discussed
                  below).

          -  Patients previously treated with InO will be eligible, unless they meet ANY of the
             following criteria:

               -  > 6 individual doses (e.g., > 2 standard cycles) were administered.

               -  Any documented hepatic toxicity observed was grade 3 or higher.

               -  The most recent dose was administered < 3 months from the initiation of study
                  treatment.

          -  For patients that have received prior allogeneic HCT, they must be >= 4 months from
             the date of stem cell infusion, with no prior history of sinusoidal obstruction
             syndrome/veno-occlusive disease (SOS/VOD), and off all treatment for graft-vs-host
             disease (GVHD) for >= 2 weeks. Patients with minimal active symptoms that can be
             controlled with topical therapies and/or the equivalent of prednisone =< 10 mg/day
             will be eligible.

          -  For patients that have received other forms of cellular immunotherapy (e.g., chimeric
             antigen receptor-modified [CAR] T cells), they must be >= 21 days from cell infusion,
             and any specific manifestations of cytokine release syndrome or neurologic toxicity
             attributable to the cellular therapy have completely resolved (i.e., < grade 1)

          -  Patients with a known history of chronic liver disease, including but not limited to
             cirrhosis, steatohepatitis, and chronic viral hepatitis. Patients with a history of
             GVHD of the liver will be permitted, provided they meet all of the other eligibility
             criteria.

          -  Patients with isolated testicular or central nervous system disease.

          -  Known hypersensitivity or intolerance to any of the agents under investigation.

          -  May not be pregnant or nursing.